The MMRF Blog - Multiple Myeloma Research Foundation

The MMRF Blog

Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study.

Lesokhin AM, Ansell SM, Armand P, Scott EC, Halwani A, Gutierrez M, Millenson MM, Cohen AD, Schuster SJ, Lebovic D, Dhodapkar M, Avigan D, Chapuy B, Ligon AH, Freeman GJ, Rodig SJ, Cattry D, Zhu L, Grosso JF, Bradley Garelik MB, Shipp MA, Borrello I, Timmerman J. J Clin Oncol. 2016 Jun 6. pii: JCO659789. [Epub ahead of print] READ MORE

Posted: June 23, 2016

Phase 1 study of tabalumab, a human anti-B-cell activating factor antibody, and bortezomib in patients with relapsed/refractory multiple myeloma.

Raje N, Faber E, Richardson PG, Schiller G, Hohl RJ, Cohen AD, Forero A, Carpenter S, Nguyen TS, Conti I, Kaiser C, Cronier DM, Wooldridge JE, Anderson KC. Clin Cancer Res. 2016 Jun 10. pii: clincanres.0201.2016. [Epub ahead of print] READ MORE

Posted: June 23, 2016

Effects of IL-8 Up-Regulation on Cell Survival and Osteoclastogenesis in Multiple Myeloma.

Herrero AB, García-Gómez A, Garayoa M, Corchete LA, Hernández JM, San Miguel J, Gutierrez NC. Am J Pathol. 2016 Jun 11. pii: S0002-9440(16)30113-4. doi: 10.1016/j.ajpath.2016.04.003. [Epub ahead of print] READ MORE

Posted: June 23, 2016

Page 21 of 87« First...10...1920212223...304050...Last »